MARKET

MRVI

MRVI

MARAVAI LIFESCIENCES HOLDINGS, INC.
NASDAQ

Real-time Quotes | Nasdaq Last Sale

28.15
-1.01
-3.46%
Closed 17:46 11/30 EST
OPEN
29.16
PREV CLOSE
29.16
HIGH
29.50
LOW
27.73
VOLUME
1.69M
TURNOVER
--
52 WEEK HIGH
32.46
52 WEEK LOW
25.56
MARKET CAP
7.26B
P/E (TTM)
153.99
1D
5D
1M
3M
1Y
5Y
News
Financial
Releases
Corp Actions
Analysis
Profile
December Will Be The Big IPO Finale Of 2020
We are getting close to the end of 2020. It's been a year like no other, the year where everything was in the shade of a global pandemic.
Benzinga · 5d ago
The Daily Biotech Pulse: Revance's DAXI Regulatory Decision, Reata Slips On FDA Feedback, Liquidia Setback
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 24)
Benzinga · 5d ago
Maravai LifeSciences Announces Closing of Initial Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares
SAN DIEGO, Nov. 24, 2020 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, today announced the closing of its initial public offering of 69,000,000 shares of Class A common stock, including the full exercise of the underwriters’ option to purchase up to 9,000,000 additional shares of Class A common stock, at a public offering price of $27 per share. The aggregate gross proceeds to Maravai from the offering were approximately $1,863,000,000, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering were offered by Maravai. Maravai’s Class A common stock began trading on the Nasdaq Global Select Market on November 20, 2020 under the symbol "MRVI." Morgan Stanley, Jefferies and Goldman Sachs & Co. LLC acted as joint book-running managers for the offering. BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel and KeyBanc Capital Markets also acted as joint book-running managers, and Academy Securities, Loop Capital Markets, Penserra Securities LLC and Tigress Financial Partners acted as co-managers for the offering.Perella Weinberg Partners L.P. served as capital markets advisor to Maravai. Kirkland & Ellis LLP provided legal counsel to Maravai and Davis Polk & Wardwell LLP provided legal counsel to the underwriters.A registration statement on Form S-1 relating to these securities was filed with the U.S. Securities and Exchange Commission (“SEC”) and became effective on November 19, 2020. The offering was made only by means of a prospectus. A copy of the final prospectus relating to the securities has been filed with the SEC and may be obtained from: Morgan Stanley & Co. LLC, Attention: Prospectus Department, 180 Varick Street, 2nd Floor, New York, NY 10014, or by email at prospectus@morganstanley.com; Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, by telephone at 877-821-7388 or by email at Prospectus_Department@Jefferies.com; or Goldman Sachs & Co. LLC, Attention: Prospectus Department, 200 West Street, New York, NY 10282, by telephone at 866-471-2526, by facsimile at 212-902-9316 or by email at prospectus-ny@ny.email.gs.com.This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.About Maravai Maravai is a leading life sciences company providing critical products to enable the development of drug therapies, diagnostics, novel vaccines and support research on human diseases through its portfolio of companies and their proprietary capabilities and products. Maravai’s companies are leaders in providing products and services in the fields of nucleic acid synthesis, bioprocess impurity detection and analysis, and protein labeling and detection to many of the world's leading biopharmaceutical, vaccine, diagnostics, and cell and gene therapy companies. CONTACT: Investor and Media Contact Sara Michelmore MacDougall +1 781-235-3060 maravai@macbiocom.com
GlobeNewswire · 6d ago
The Daily Biotech Pulse: Alnylam's Oxluma Snags Early FDA Approval, DBV Chief Scientific Officer To Depart, Decision Day For Liquidia
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23)
Benzinga · 6d ago
Last Week's IPO Recap
Last week brought us six new IPOs. Among these, breast cancer biotech company Olema Pharmaceuticals (NASDAQ: OLMA) led the way as the week's top performer while its stock skyrocketed 157% on its first day. Olema Pharmaceuticals was the only one to hurry up and go public before the holiday.
Benzinga · 11/23 17:45
GTCR-Backed Maravai LifeSciences, Sotera Health Rise in Debuts
Maravai LifeSciences Holdings Inc. and Sotera Health Co. -- both backed by the private equity firm GTCR -- rose in their trading debuts after raising a combined $2.7 billion in initial public offerings.
Bloomberg · 11/20 23:09
Sotera Health IPO Prices At High End Of Range; Shares Surge
Investor's Business Daily · 11/20 21:18
Maravai IPO Raises $1.62 Billion For Provider Of Drug-Testing Services
Investor's Business Daily · 11/20 21:17
More
Forecast
EPSBVPSCFPS
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of MRVI. Analyze the recent business situations of MARAVAI LIFESCIENCES HOLDINGS, INC. through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
  • Performance
  • Asset Allocation
  • Dividend History
No Data
No Data
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now
About MRVI
Maravai LifeSciences Holdings, Inc. is a life sciences company. The Company provides products that enables the development of drug therapies, diagnostics, vaccines and support research on human diseases. The Company's segments include Nucleic Acid Production, Biologics Safety Testing, and Protein Detection. The Nucleic Acid Production segment manufactures and sells products used in the fields of gene therapy, nucleoside chemistry, oligonucleotide therapy and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). Its Biologics Safety Testing segment sells specialized analytical products for use in biologic manufacturing process development, including custom product-specific development antibody and assay development services. The Company's Protein Detection segment sells labeling and detection reagents for researchers in immunohistochemistry.
More
Hot Stocks
Symbol
Price
%Change

Webull offers kinds of Maravai Lifesciences Holdings Inc stock information, including NASDAQ:MRVI real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, MRVI stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading MRVI stock methods without spending real money on the virtual paper trading platform.